BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 25
• 26
• 27
• 28
• 29

• Drug Development

  Eisai Inc. Release: Combination Of Lenvatinib And Pembrolizumab Results In Notable Response Rates For Patients With Advanced Renal Cell Carcinoma Based On Interim Analysis Of Ongoing Phase Ib/II Trial

  September 11, 2017

   · 

  16 min read
• Drug Development

  IRX Therapeutics Presents Positive IRX-2 Phase IIa Head And Neck Squamous Cell Carcinoma Clinical Results At The European Society For Medical Oncology Annual Congress 2017

  September 11, 2017

   · 

  3 min read
• Drug Development

  Novartis AG Phase III Study Demonstrates Adjuvant Tafinlar + Mekinist Reduced The Risk Of Disease Recurrence By 53% In Patients With Resected BRAF V600 Mutation-Positive Melanoma

  September 11, 2017

   · 

  18 min read
• Business

  QPharma, Inc. Names Badal Shah As Managing Director, KOL And Targeting

  September 11, 2017

   · 

  2 min read
• Drug Development

  Lycera Presents Encouraging Safety Results From Phase I ARGON Study Of LYC-55716 At The European Society For Medical Oncology (ESMO) Congress

  September 11, 2017

   · 

  4 min read
• Drug Development

  Deciphera Reports Updated Data From Ongoing Phase I Clinical Study Of DCC-2618 At The European Society Of Medical Oncology 2017 Congress

  September 11, 2017

   · 

  4 min read
• Drug Development

  Zymeworks Presents Additional Safety And Anti-Tumor Activity Data From The Ongoing Phase 1 Study Of ZW25 At The European Society For Medical Oncology 2017 Congress (“ESMO”)

  September 11, 2017

   · 

  9 min read
• Drug Development

  Syros Pharma Presents PK And PD Data At ESMO For SY-1425, Its First-In-Class Selective Rara Agonist, In Genomically Defined AML And MDS Patients

  September 11, 2017

   · 

  8 min read
• Drug Development

  Medivir Announces Janssen To Discontinue Development Of JNJ-4178 For Hepatitis C

  September 11, 2017

   · 

  1 min read
• Business

  Cannimed Reports Financial Results For Q3 2017

  September 11, 2017

   · 

  2 min read